Clinical Trial Update: Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating trastuzumab combined with erlotinib as first-line therapy for metastatic breast cancer with HER2 overexpression has completed; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-04-11